Crown Forest Investment Limited Evaluates Biotech Sector Surge in 2025
illi News/10303874

BRIDGEVIEW, Ill. - illiNews -- Crown Forest Investment Limited, a Hong-Kong based investment advisory firm with sector-specific expertise, today released its mid‑year assessment of the biotechnology industry's strong performance in 2025. The report highlights multiple growth drivers—from breakthrough innovations to mega-deals—underscoring biotech's transformation into a growth powerhouse.

Record Market Expansion

According to industry analysts, the global biotech market is projected to reach $546 billion in 2025, up from $483 billion in 2024—a compound annual growth rate of approximately 13%.

Explosive Licensing Momentum

U.S. pharmaceutical firms have entered 14 licensing agreements worth $18.3 billion with Chinese biotech companies in H1 2025, compared to just two such deals during the same period last year.

More on illi News

• $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
• Chicago: Mayor Johnson, City Officials Honor 1995 Heat Wave Victims, Forgotten WWII Hero Emilio Aguirre with Full Military Funeral Honors
• $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
• Disposable Vape Ban Spurs Hayati Innovation
• Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work

These deals focused on innovative targeted-cancer and first-in-class therapies, marking a pivotal shift in global R&D sourcing.

Strategic M&A Activity

Big Pharma continues to bolster its pipelines through acquisitions: Eli Lilly is nearing a $1.3 billion deal for gene-editing pioneer Verve Therapeutics, while BioNTech recently agreed to acquire CureVac for $1.25 billion—both moves centered on next-gen therapeutic platforms.

Mega‑Rounds Define Financing Landscape

Biotech venture capital has shifted toward large-scale "megarounds." In Q1 2025, 75% of private biotech funding—approximately $4.1 billion—was raised in rounds exceeding $100 million.

This reflects increasing investor preference for later-stage opportunities.

Innovation Trends: AI & Gene Editing

Advancements in AI‑driven drug discovery and gene-editing—particularly CRISPR therapies—are accelerating clinical acceleration and shaping next-gen pipelines.

More on illi News

• Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
• Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
• Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
• Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
• Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally

Crown Forest Investment Limited

Crown Forest Investment Limited has steadily but firmly established itself as a go-to source for investors looking for information before it hits the streets since its founding in 1989. Join us right now and let us show you the route to a brighter future. Please contact our team representative today and learn more about this unique financial building experience. Our aim is to make your wealth building journey, a simple and enjoyable experience. https://crownforestil.com/

Shira Co
Press Release Officer
+85232482266
info@crownforestil.com
15/F Melbourne Plaza No. 33 Queen's Road, Central, Hong Kong